PHVS
Pharvaris N.V.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
4.94
P/S
0.00
EV/EBITDA
-8.26
DCF Value
$5.95
FCF Yield
-8.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-67.1%
ROA
-49.0%
ROIC
-27.5%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $0.00 | $-37.1M | $-0.60 |
| Q2 2025 | $0.00 | $-45.5M | $-0.83 |
| Q1 2025 | $0.00 | $-46.3M | $-0.85 |
| Q4 2024 | $0.00 | $-37.1M | $-0.64 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
NL
Exchange
NASDAQ
Beta
-2.58
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks and is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients and is under Phase 1 clinical trial. It operates in the Netherlands, Switzerland, and the United States. The company was incorporated in 2015 and is based in Leiden, the Netherlands.